Journal article

Publication year: 2019

Pages: 508-517

Journal: Zeitschrift für Gastroenterologie

Volume number: 57

Issue number: 4

ISSN: 0044-2771

eISSN: 1439-7803

DOI Link: https://doi.org/10.1055/a-0784-8877

Publisher: Georg Thieme Verlag

Abstract: 

Nonalcoholic fatty liver disease (NAFLD) includes nonalcoholic fatty liver (NAFL), nonalcoholic steato hepatitis (NASH) and NASH cirrhosis. NAFLD is the leading cause of liver diseases in the Western world (Central Europe, United States). The NAFLD incidence increases because of increasing type 2 diabetes and obesity. This article reviews the scientific findings of epidemiology, diagnostic, and therapeutic management of NAFLD. Lifestyle modifications (low-caloric Mediterranean diet and exercise training) to reduce weight are a major factor in the treatment of NAFLD.

Pharmacological therapies may be useful in patients with NASH and fibrosis as well as nonresponders to lifestyle modifications. Currently, however, no pharmacological substances are approved for the indication NASH.

Harvard Citation style: Roeb, E. and Geier, A. (2019) Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments, Zeitschrift für Gastroenterologie, 57(4), pp. 508-517. https://doi.org/10.1055/a-0784-8877

APA Citation style: Roeb, E., & Geier, A. (2019). Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Zeitschrift für Gastroenterologie. 57(4), 508-517. https://doi.org/10.1055/a-0784-8877